Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26141744 | 0.88 | L3MBTL1 (0.45) | L3MBTL1KDM4ANAMPTGLSCA1 | |
| SCHEMBL21455931 | 0.88 | L3MBTL1 (0.45) | L3MBTL1KDM4ANAMPTGLSCA1 | |
| SCHEMBL2841433 | 0.85 | GABRP (0.46) | L3MBTL1KDM4ANAMPTGLSCA1 | |
| SCHEMBL17309330 | 0.85 | KDM4A (0.43) | L3MBTL1KDM4ANAMPTCA1CA2 | |
| SCHEMBL16020311 | 0.83 | KDM4A (0.44) | L3MBTL1KDM4ANAMPTCA1CA2 | |
| SCHEMBL23705856 | 0.83 | GLS (0.47) | KDM4ANAMPTGLSCA1CA12 | |
| SCHEMBL19558646 | 0.82 | KDM4A (0.43) | L3MBTL1KDM4ANAMPTGLSCA1 | |
| SCHEMBL10547182 | 0.82 | ATR (0.46) | L3MBTL1KDM4ANAMPTCA1CA2 | |
| SCHEMBL14228526 | 0.82 | BRD4 (0.48) | L3MBTL1KDM4ANAMPTGLSBRD4 | |
| SCHEMBL29634114 | 0.82 | ATR (0.46) | L3MBTL1KDM4ANAMPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12152014-B2 | Therapeutic compounds and compositions | eXlthera Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12084414-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116444506-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3102200-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-108892661-B | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20220281813-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | L3MBTL1 4764/4885KDM4A 837/4885NAMPT 1969/4885 |
| US-12152014-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | L3MBTL1 4764/4885KDM4A 837/4885NAMPT 1969/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | L3MBTL1 4764/4885KDM4A 837/4885NAMPT 1969/4885 |
| US-12084414-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | L3MBTL1 4520/4885KDM4A 1080/4885NAMPT 2249/4885 |
| US-20220281813-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | L3MBTL1 4520/4885KDM4A 1080/4885NAMPT 2249/4885 |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | L3MBTL1 4520/4885KDM4A 1080/4885NAMPT 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.